ClinicalTrials.Veeva

Menu

Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control

U

University of Toronto

Status

Enrolling

Conditions

Prediabetic State
Hyperglycemia
Obesity
Diabetes Mellitus, Type 2

Treatments

Behavioral: Mid (9:30 - 18:30) TRE
Behavioral: Early (7:00 - 16:00) TRE
Behavioral: Late (12:00 - 21:00) TRE

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

This study will evaluate the effectiveness of time-restricted eating (TRE), which is a form of intermittent fasting. When performing TRE, individuals consume all of their calories within a specific time window and then only consume water or other no calorie drinks the rest of the day. TRE is performed each day. There is no restriction on the quality or amount of food that people can consume during their eating window (ad libitum eating) with TRE, which can last anywhere from 4 to 12 hours. We are comparing three different 9-hour eating windows to determine whether the start and stop time of the eating window impact blood sugar control in individuals with obesity who also have or are at risk for type 2 diabetes. We also aim to determine if there are differences in the effects of the timing of eating window between males and females.

Full description

The overarching aim of this study is to evaluate the interactions between TRE window timing, type 2 diabetes status, and sex among individuals with obesity. The first objective is to compare the effects of three 9-h TRE window times (early: 7:00-16:00 h, mid: 9:30-18:30 h, delayed: 12:00-21:00 h) on real-time, free-living glycemic control. The second objective is to determine if type 2 diabetes status (type 2 diabetes versus prediabetes or moderate+ risk for type 2 diabetes aka at risk for type 2 diabetes) modifies the effect of eating window timing on glycemic control outcomes. The exploratory objectives include: 1) determine whether sex modifies TRE adherence or the effect of TRE on metabolic changes relative to control; and 2) to compare changes in dietary intake, body weight, and blood pressure within and between early, mid, and delayed TRE. We have the following hypotheses related to these objectives:

  1. The early TRE window will result in the most favourable glycemic control outcomes but also the lowest participant acceptability followed by mid and delayed TRE.
  2. There will be larger differences in glycemic control outcomes between the TRE window timings among those with type 2 diabetes compared to those at risk for type 2 diabetes.
  3. TRE adherence and changes in glycemic control, and weight loss with all TRE window times (relative to control) will be higher in men vs women.
  4. Energy, carbohydrate, and sugar intake, body weight, and blood pressure will decrease during TRE, but with no differences by window timing.

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged >18 years
  • Body mass index >30 kg/m2 and <50 kg/m2
  • Have access to an Apple or Android cellphone with Bluetooth.
  • Have type 2 diabetes or be at risk for type 2 diabetes (defined as high (33+) Canadian Diabetes Risk Score)

Exclusion criteria

  • Individuals with type 2 diabetes will be excluded if: (1) currently on >3 monotherapies for diabetes, (2) have had diabetes therapy dosage changes <3 months, (3) self-reported hemoglobin A1c >9.0%, (4) taking exogenous insulin, or (5) taking sulfonylureas

  • The following exclusion criteria applies to all potential participants:

    1. History of or referral for bariatric surgery
    2. Weight loss >5% in the last 3 months
    3. Taking antiobesity (weight loss) medications
    4. Body weight >340lbs
    5. Diagnosed cognitive disorder that precludes them from giving consent
    6. Inability or unwillingness to change their eating window to follow those prescribed in the study
    7. Currently eating during <12 hour period on 5 or more days/week
    8. Physician-diagnosed eating disorder

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

120 participants in 4 patient groups

Early (7:00-16:00h) TRE
Experimental group
Description:
Participants will be asked to eat ad libitum between the hours of 7:00 - 16:00 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 7:00 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.
Treatment:
Behavioral: Early (7:00 - 16:00) TRE
Mid (9:30-18:30h) TRE
Experimental group
Description:
Participants will be asked to eat ad libitum between the hours of 9:30 - 18:30 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 9:30 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.
Treatment:
Behavioral: Mid (9:30 - 18:30) TRE
Late (12:00-21:00h) TRE
Experimental group
Description:
Participants will be asked to eat ad libitum between the hours of 12:00 - 21:00 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 12:00 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.
Treatment:
Behavioral: Late (12:00 - 21:00) TRE
Control
No Intervention group
Description:
During the first week of the study, participants will be asked to eat as they normally do, and to not make any changes regarding when they are stopping or starting eating.

Trial contacts and locations

1

Loading...

Central trial contact

Amy A Kirkham, PhD; Rebecca AG Christensen, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems